Study: Early Identification Needed for Mesothelioma Advances

Professor John Cherrie at Heriot-Watt University in the United Kingdom believes future treatment advances and improved patient outcomes for mesothelioma rests with a formula to better identify and screen high-risk patients. It could make an early diagnosis of the asbestos-related cancer much more common. Cherrie said the current standard — which typically results in a late-stage diagnosis and a poor prognosis — prevents novel treatment studies and the development of any pre-emergent strategy to combat the aggressive cancer. “We don’t pretend to have a medical cure that will help immediately, but until we can start identifying patients earlier, we can’t even try out what might work,” Cherrie, an occupational medicine specialist in the School of Engineering and Physical Sciences at Heriot-Watt, told “The patients are usually too sick. It’s tough to make progress that way.” Cherrie is the lead author in a study published recently in the International Journal of Hygiene and Environmental Health, detailing the asbestos-exposure formula he believes would work. “Right now, we don’t have a way of identifying early-stage disease,” he said. “Usually by the time it is diagnosed, it’s virtually untreatable. We want to find a way to change that.” Pre-Emergent Treatment Strategies Mesothelioma is caused almost exclusively by exposure to toxic asbestos, typically in long-term occupationa...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Activity emission potential biomarkers for mesothelioma chemoprophylaxis strategies early diagnosis mesothelioma Early identification of mesothelioma early screening asbestos Heriot-Watt University high-risk mesothelioma indwelling pleural Source Type: news

Related Links:

CONCLUSIONS: The risks of perioperative morbidity and mortality after CRS and HIPEC are analogous to any other major gastrointestinal surgery. CRS and HIPEC should remain a treatment option for highly selected patients in whom a curative or life prolonging treatment is a pursuit and should be performed in high volume specialized institutions. PMID: 29589675 [PubMed - as supplied by publisher]
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss. The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma. All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers. The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion The combined treatment for peritoneal carcinomatosis may be performed safely with acceptable morbidity and mortality in a specialized unit setting. Although over half of patients underwent normothermic intraperitoneal chemotherapy, our results were comparable to results from others centers.
Source: Journal of Coloproctology - Category: Gastroenterology Source Type: research
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma. She wants to show it with this groundbreaking clinical trial. “We think [cryotherapy] could play an important role in treatment,” Blackmon told “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.” Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitr...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news
This study investigated the expression and DNA methylation of SFRP genes in MPM cells lines with and without demethylation treatment. Sixty-six patient FFPE samples were analysed and have showed methylation of SFRP2 (56%) and SFRP5 (70%) in MPM. SFRP2 and SFRP5 tumour-suppressive activity in eleven MPM lines was confirmed, and long-term asbestos exposure led to reduced expression of the SFRP1 and SFRP2 genes in the mesothelium (MeT-5A) via epigenetic alterations. Finally, DNA methylation of SFRPs is detectable in MPM patient plasma samples, with methylated SFRP2 and SFRP5 showing a tendency towards greater abundance in pat...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Conclusion The use of genetic testing and preoperative imaging studies should be considered to be invaluable tools for detecting synchronous malignancies. Practicing physicians should pay more attention to the risk of simultaneous separate primary malignancies.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Conclusions Data showed an important variability in volume of patients per center, selection of cytostatic agents, professional training and safety measures applied. The standardization of CRS/HIPEC procedures based on the best available evidence, the individualization of patients and the consensus among professionals, constitute an important part of the basis that will allow us to improve results of this complex procedure.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionsPostoperative BNP measurement after CRS + HIPEC may guide postoperative fluid resuscitation and facilitate identification of patients at risk for major and/or cardiopulmonary complications.
Source: Journal of Surgical Oncology - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told “Clearly, this drug can change the natural history of this tumor.” Bevaci...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news
Conclusions • Physicians should have no hesitation prescribing natural progesterone. The evidence is clear that progesterone does not cause breast cancer. Indeed, progesterone is protective and preventative of breast cancer. PMID: 29055286 [PubMed - as supplied by publisher]
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Tags: Altern Ther Health Med Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | CT Scan | Environmental Health | Epidemiology | Immunotherapy | Mesothelioma | Occupational Health | Respiratory Medicine | Study | Toxicology | UK Health | X-Ray